Overview
A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model
Status:
Completed
Completed
Trial end date:
2014-07-01
2014-07-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study is designed to compare the antiviral effect of ALS-008176 compared to a placebo control in the respiratory syncytial virus challenge model.Phase:
Phase 2Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Alios Biopharma Inc.
Criteria
Inclusion Criteria:- Age 18 to 45 years, inclusive.
- In good health with no history of major medical conditions
- A total body weight ≥ 50 kg and a body mass index (BMI) of > 18kg/m2.
Exclusion Criteria:
- Acute or chronic medical illness
- Positive for Human Immunodeficiency Virus, Hepatitis B or C
- Nose or nasopharynx abnormalities
- Abnormal lung function